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Abstract
Background: Fumaric acid esters (FAE) are a group of compounds which are currently under investigation as an oral
treatment for relapsing-remitting multiple sclerosis. One of the suggested modes of action is the potential of FAE to exert a
neuroprotective effect.
Methodology/Principal Findings: We have investigated the impact of monomethylfumarate (MMF) and dimethylfumaric
acid (DMF) on de- and remyelination using the toxic cuprizone model where the blood-brain-barrier remains intact and only
scattered T-cells and peripheral macrophages are found in the central nervous system (CNS), thus excluding the influence of
immunomodulatory effects on peripheral immune cells. FAE showed marginally accelerated remyelination in the corpus
callosum compared to controls. However, we found no differences for demyelination and glial reactions in vivo and no
cytoprotective effect on oligodendroglial cells in vitro. In contrast, DMF had a significant inhibitory effect on
lipopolysaccharide (LPS) induced nitric oxide burst in microglia and induced apoptosis in peripheral blood mononuclear
cells (PBMC).
Conclusions: These results contribute to the understanding of the mechanism of action of fumaric acids. Our data suggest
that fumarates have no or only little direct protective effects on oligodendrocytes in this toxic model and may act rather
indirectly via the modulation of immune cells.
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Introduction
Multiple sclerosis (MS) is the most common cause of neurological
disability in young adults. Its pathology is characterised by an
inflammation-mediated demyelination and axonal loss in the
central nervous system (CNS) white and grey matter [1]. The
current treatment options for relapsing remitting MS (RRMS) are
only partially effective and need a parenteral route of administra-
tion. Still oral therapeutics, which could either prevent tissue
damage and/or support repair mechanisms are not available.
Fumaric acid esters (FAE) can be administered orally and are
currently being evaluated for the treatment of MS. A recently
published randomised, placebo-controlled phase II study showed
significant positive effects of FAE on various MRI parameters in
MS patients with relapsing-remitting MS. This study utilised a
second generation FAE formulation (BG00012) consisting of
dimethylfumaric acid (DMF) as single compound that is thought to
represent the active component of FAE [2]. The mode of action is
not yet clear, but both immunomodulatory and neuroprotective
effects are being discussed [3]. FAE have been demonstrated in
vitro to exert immunomodulatory effects on T-cells [4], B-cells [5],
and dendritic cells [6,7]. The immunomodulatory properties of
FAE were also investigated in the rodent model of myelin
oligodendrocyte glycoprotein (MOG) induced experimental auto-
immune encephalomyelitis (MOG-EAE), an animal model that
mimics several aspects of MS [8]. In mice treated with FAE a
significant therapeutic effect on the disease course could be found.
Furthermore, the numbers of microglia/macrophages but not of
T-cells were reduced in the inflammatory lesions.
Beside its immunomodulatory effects FAE bear the potential for
neuroprotective effects via detoxifying pathways. Cell culture
experiments with rat mixed glia (microglia and astrocytes) showed
an upregulation of the detoxification enzyme NAD(P)H: quinine
oxidoreductase (NQO-1), a reduction of the intracellular gluta-
thione content, and a reduction of the neurotoxic agent nitric
oxide by FAE treatment [9]. In human peripheral blood
mononuclear cells (PBMC) DMF induced an upregulation of the
anti stress protein heme oxygenase 1 (HO-1), which led to a
reduction of the intracellular glutathione content [10].
To further investigate the cytoprotective potential of FAE we
used the toxic cuprizone model of demyelination in mice. The
cuprizone model is well established to follow both demyelination
and spontaneous remyelination in the CNS white and grey matter
[11–14].
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Animals
C57BL/6 male mice were obtained from Charles River
(Sulzfeld, Germany). Animals underwent routine cage mainte-
nance once a week and were microbiologically monitored
according to Federation of European Laboratory Animal Science
Associations recommendations [15]. Food and water were
available ad libitum. All research and animal care procedures were
approved by the Review Board of the care for Animals Subjects of
the district government (Lower Saxony, Germany) and performed
according to international guidelines on the use of laboratory
animals.
Induction of demyelination and treatment with
fumarates
Demyelination was induced by feeding 8-week-old male
C57BL/6 mice a diet containing 0.2% cuprizone (bis-cyclohex-
anone oxaldihydrazone; Sigma-Aldrich Inc., St. Louis, MO)
mixed into a ground standard rodent chow for 5 weeks. Animals
were then put on standard rodent chow without cuprizone to
induce remyelination.
Cuprizone treated mice received 15mg monomethylfumarate
(MMF) or 15mg DMF per kg body weight (both from Sigma-
Aldrich Inc., St. Louis, MO) twice daily as described by Schilling
et al. [8]. MMF and DMF were diluted in 200ml 0,08% methocel/
H2O. Cuprizone mice treated with 200ml 0,08% methocel/H2O
without fumarates served as controls. For treatment oral gavage
was used to ensure exact dosing and to avoid compound
degradation. Treatment was administered starting from day 1 of
cuprizone feeding until termination.
At different time points (weeks 4, 5, and 6) animals were
perfused with 4% paraformaldehyde in phosphate buffer via left
cardiac ventricle as previously described [16]. A group size of five
to six animals was investigated at all time points. The brains were
removed, postfixed in 4% paraformaldehyde and paraffin
embedded. For light microscopy, 7mm serial paraffin sections
were cut and dried at 37uC overnight.
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as
previously described [13]. Briefly, 7mm serial sections between
bregma 20.82 and bregma 21.8 (according to mouse atlas by
Paxinos and Franklin, [17] were analysed. Sections were stained
for myelin with Luxol-fast-blue periodic acid-Schiff base (LFB-
PAS) (Sigma-Aldrich Inc., St. Louis, MO). For immunohisto-
chemistry, paraffin-embedded sections were dewaxed, rehydrated,
and boiled for 5 minutes in 10mmol/L citrate buffer (pH 6.0).
Sections were quenched with H2O2, blocked for 1 hour in
phosphate-buffered saline (PBS) containing 3% normal goat
serum, 0.1% TritonX-100, and then incubated overnight with
primary antibody. The following primary antibodies were used:
For myelin proteins proteolipid protein (PLP) (mouse IgG, Serotec,
Du ¨sseldorf, Germany), myelin basic protein (MBP) (mouse IgG,
Sternberger Monoclonals Inc., Berkeley, CA), myelin oligoden-
drocyte glycoprotein (MOG) (mouse IgG, 1:2 hybridoma super-
natant, gift from C. Linington), for astrocytes glial fibrillary acidic
protein (GFAP) (mouse IgG, Chemicon, Hampshire, UK), for
oligodendrocytes Nogo-A (rabbit IgG, Chemicon, Hampshire,
UK), for oligodendrocyte precursor cells (OPC) Olig-2 (rabbit
IgG, Abcam, Cambridge MA), for activated microglia Mac-3 (rat
IgG, BD Pharmingen, Germany), and for axonal damage
Alzheimer precursor protein (APP) (mouse IgG, 1:800 Chemicon).
After washing, sections were further incubated with biotinylated
secondary antibody (Vector Laboratories, Burlingame, UK) for
1hour, followed by peroxidise-coupled avidin-biotin complex
(ABC Kid, Vector Laboratories). Reactivity was visualised with
diamino-3,39benzidine (Dako Cytomation, Hamburg, Germany).
Isotype controls and staining without primary antibody were used
as controls. There was no significant non-specific staining of
mouse immunoglobulin in mouse tissue.
Determination of de- and remyelination in white and
grey matter
To detect de- and remyelination in the corpus callosum myelin
stained sections for LFB, MBP, MOG, and PLP were scored by
three blinded observers using a scale from 0 (complete demyelin-
ation) to 3 (normal myelin). Cortical myelin was scored using a
scale from 0 (complete demyelination) to 4 (normal myelin).
Scoring of myelination was done at the light microscope
(Olympus, Hamburg, Germany) as previously described [12,13].
Quantification of glial reaction
Cells positive for Nogo-A, Olig-2, GFAP, and Mac-3 with
identified nucleus (counterstained with haematoxylin) were
counted left and right of the midline within the corpus callosum
within an area of at least 0.125mm
2 using a magnification of 640
(Olympus, Hamburg, Germany). For axonal damage Alzheimer
precursor protein (APP) positive ovoids were counted as described
above. The results were expressed as cell number per mm
2.
Mixed glial cell cultures
Primary cultures of mixed glial cells were prepared from
neonatal Sprague–Dawley rat cerebra as described [18]. Brains
were freed from meninges under a dissecting microscope,
dissociated mechanically and enzymatically with trypsin and
DNAse (both from Sigma-Aldrich Inc., St. Louis, MO). Finally,
a single cell suspension was generated by shearing through a glass
Pasteur pipette with flamed tip. Cells were cultured in DMEM
including glutamine (Gibco, Karlsruhe, Germany) supplemented
with 10% heat inactivated fetal calf serum (FCS, Biochrom, Berlin,
Germany), 50 U/ml penicillin, and 50 mg/ml streptomycin
(Sigma-Aldrich Inc., St. Louis, MO). After several days a confluent
astrocytic monolayer developed with both microglia and OPC on
top. Cells were cultured for 7 to 10 days before subjected to
cytotoxicity assays.
Oligodendroglial cell line
CG4 cells [19] were kept in a proliferative state in DMEM
containing 30% medium conditioned by the neuroblastoma cell
line B104 (B104CM) [20], 1% ITS+tissue culture supplement
(Becton Dickinson, Bedford, MA., USA), biotin, putrescine,
progesterone and antibiotics in poly-L-lysine coated flasks.
Cytotoxicity assay
Potential cytoprotective effects of DMF and MMF were
measured in the oligodendroglial cell line CG4 [19]. Oligoden-
droglial cell death was induced by the toxic substances sodium
nitroprusside (SNP) or H2O2. For analyses 10
4 cells were seeded in
a poly-L-lysine coated 96 well plate (Nunc, Wiesbaden, Germany)
and were pre-treated 24h with different MMF and DMF
concentrations (5, 10, 50mM/ml). Then the toxic agent (1 mM
SNP, or 0.09mM H2O2,) was added for another 24h. At the end of
the incubation period medium was exchanged by 100mlo f
medium containing 10% Alamar-BlueH (TRINOVA Biochem
GmbH, Gieben, Germany). After 4 to 6h the colour change of the
metabolised AlamarBlueH was measured by the optical density
Fumatates in CNS Demyelination
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Labinstruments GmbH, Crailsheim, Germany). The reduction of
AlamarBlueH is an indirect measurement of cell numbers and
produces linear results with a high specificity and sensitivity
[21,22]. Cell numbers for each well were calculated by linear
regression in relation to a standard curve derived from a daily
control of untreated cells plated at different densities [22,23].
Nitric oxide production
The influence of DMF and MMF on nitric oxide production of
microglia was tested. Nitrite, the stable end product of nitric oxide
(NO), was measured with the Griess reaction [24]. For analyses
10
4 microglia were seeded in a 96 well plate (Nunc, Wiesbaden,
Germany) and were pre-treated 24h with different MMF and
DMF concentrations (5, 10, 50mM/ml). Then 10ng/ml lipopoly-
saccharide (LPS) was added for another 24h. For the measure-
ments microglia cell culture supernatant (100ml) was added to an
equal volume of Griess reagent (0.1% naphtylethylene-diaminedi-
hydrochloride, 1% sulfanilamide in 2.5% H3PO4, all from Sigma).
The reaction was allowed to proceed for 15min at room
temperature before the OD at 540nm was measured in an ELISA
reader (SLT Spectra, SLT Labinstruments GmbH, Crailsheim,
Germany). The concentration of nitrite was determined by linear
regression from a standard curve using known concentrations of
sodium nitrite (Sigma-Aldrich Inc., St. Louis, MO) in culture
medium.
Induction of apoptosis of mouse PBMC
To measure the effect of MMF and DMF on PBMC, blood
from mice killed by cervical dislocation was collected by heart
puncture into EDTA vacutainer tubes (Sarstedt, Newton, NC).
Blood was diluted 1/1 with Dulbecco’s PBS. PBMC were
separated by density gradient centrifugation using Biocoll (FicollH)
separating solution (Biochrom, Berlin, Germany). The PBMC
layer was collected and washed twice with Dulbecco’s PBS and
then resuspended at a concentration of 1610
6 cells/ml in DMEM
(GIBCO 41966) with 10% heat-inactivated FBS (Biochrom,
Berlin, Germany) and 1% penicillin-streptomycin (Sigma-Aldrich
Inc., St. Louis, MO). 3610
5 cells were plated in a Flat Bottom 24-
Well plate (Sarstedt, Newton, NC), and treated with MMF and
DMF in different concentrations (10, 20, and 50mM/ml). 10ml
methanol was used as solvent control. PBMC without any addition
of MMF or DMF or methanol served as a medium control. Cells
were incubated for 48h. Cell death and apoptotic cells were
assessed by using FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen, Germany). After 20min incubation with FITC
Annexin V (1:100) and PI (1:100) dead cells and apoptotoc cells
were determined by FACS analysis on a FACScalibur Becton-
Dickinson flow cytometer.
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA) followed by the Fisher-protected least-
significant difference test for post hoc comparison if appropriate.
All data are given as arithmetic means 6 standard error of the
mean (SEM). P values of the different ANOVAs are given in the
Results, while group comparisons derived from post hoc analysis
are provided in the figures. In the latter case, significant effects are
indicated by asterisks (*P,0.05; **P,0.01; ***P,0.001).
Results
MMF and DMF have only minor effects on remyelination
in the corpus callosum
To evaluate the sequential loss and re-expression of myelin the
histochemical LFB staining and immunohistochemical myelin
protein stainings for MBP, PLP, and MOG were used. At week 4
there were no differences in the myelin scores for all investigated
myelinproteinsand LFBstaining. Atweek 5,when remyelinationin
the corpus callosum starts, there was a small but significant increase
of LFB staining intensity in MMF treated animals (one-way
ANOVA p=0.01, Fig. 1A, A1–C3). In DMF treated mice this
increase was not significant. At week 6 nearly the same amount of
myelin was seen in the corpus callosum indicating that remyelina-
tion remained on the same level. As described previously, the
dynamics of myelin protein expression differed between myelin
proteins in the corpus callosum [25]. Maximal degradation of MBP
was detectable after 4 weeks of cuprizone exposure. At week 5 of
cuprizone feeding re-expression of MBP was evident and further
increased in week 6. Treatment with MMF resulted in significantly
higher MBP expression after 5 weeks of cuprizone exposure, while
DMF treated mice showed higher MBP expression in week 6 (one-
way ANOVA p,0.0001, Fig. 1B). For PLP and MOG maximal
degradation was detectable after 5 weeks of cuprizone feeding. In
week 6 MMF treated mice showed higher re-expression of MOG
(one-way ANOVA p,0.0001, Fig.1C) and PLP (one-way ANOVA
p,0.0001, Fig. 1D).
To determine cortical myelination, PLP and MBP stained
section were analyzed. LFB and MOG stained brain sections were
not investigated, because of their low sensitivity to demonstrate
cortical myelin [12]. In the cortex, both MBP and PLP expression
showed no significant differences for MMF and DMF treated mice
at the time points investigated (Fig. 2A–B).
MMF and DMF are not protective for OPC,
oligodendrocytes, and axons
OPC were visualised using immunohistochemical staining for
Olig-2, while mature oligodendrocytes were demonstrated by
Nogo-A staining [26]. The density of Olig-2 and Nogo-A positive
cells in the corpus callosum was not significantly changed in
animals treated with MMF or DMF compared to control mice
(Fig. 3A–B).
In the demyelinated corpus callosum after 6 weeks of cuprizone
feeding the axonal damage is only minor [27]. Here, axonal injury,
as detected by APP immunostaining, was not significantly changed
in MMF or DMF treated animals as compared to control mice
(Fig. 3C).
Fumarates do not influence microgliosis and astrocytosis
in the cuprizone model
In order to study activated microglia during cuprizone
treatment we used the marker Mac-3 [28]. Treatment with
MMF and DMF showed no difference in microgliosis in the
corpus callosum (Fig. 3D). The extent of astrocytosis that occurs
Figure 1. Influence of DMF and MMF on de- and remyelination in the corpus callosum. Myelination in the corpus callosum was
demonstrated by scoring of LFB-PAS stained sections (A) and the myelin proteins MBP (B), MOG (C), and PLP (D). In the corpus callosum score of 0
represents complete loss of myelin while score of 3 represents normal amount of myelin. Results are shown as means 6 SEM. Significant post hoc
effects versus controls (CO) are indicated by asterisks (*p,0.05, **p,0.01). In E1-G3 representative images of LFB-PAS stained sections of the corpus
callosum are shown. Scale bars: 100 mm.
doi:10.1371/journal.pone.0011769.g001
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affected by either MMF or DMF (data not shown).
Fumarates do not protect oligodendroglial cells from
oxidative injury in vitro
To further investigate possible cytoprotective properties of
MMF and DMF, we used an in vitro model that utilised the toxic
substances H2O2 as oxygen radical donor and SNP as nitric
oxide (NO) donor on CG4 OPC. MMF and DMF had no
significant protective effect on both toxic injuries, suggesting
that there is no direct cytoprotective effect of fumarates on OPC
(Fig. 4A–C).
DMF reduce the nitric oxide burst in microglia in vitro
In order to study the effects of MMF and DMF on NO burst in
microglia we used primary rat microglia in vitro. After LPS induced
Figure 3. Influence of DMF and MMF on glial reactions during de- and remyelination. Graphs represent cell numbers of Nogo-A (A), Olig-2
(B), and Mac-3 (D) positive cells in the corpus callosum. In C results of the APP staining to demonstrate axonal damage during cuprizone treatment
are shown. Cell numbers are given as cells/mm
2. Results are shown as means 6 SEM.
doi:10.1371/journal.pone.0011769.g003
Figure 2. Influence of DMF and MMF on de- and remyelination in the cortex. Cortical myelin was demonstrated by scoring of MBP (A) and
PLP (B). In the cortex score of 0 represents complete myelin protein loss, score of 4 represents normal myelin protein amount. Results are shown as
means 6 SEM.
doi:10.1371/journal.pone.0011769.g002
Fumatates in CNS Demyelination
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contrast, DMF significatly reduced the amount of nitrite
production in a dose dependent manner (one-way ANOVA
p,0.0001, Fig. 5).
DMF but not MMF induces dose dependently cell death
in mouse PBMC
Since fumarates are known to induce apoptosis in human T-
cells [4] we investigated the effects of MMF and DMF on mouse
PBMC. As shown in Fig. 6A and B different MMF doses did not
induce cell death as measured for PI and annexin positive cells. In
contrast, DMF treatment increased the numbers of PI positive as
well as annexin positive cells in a dose dependent manner (for both
one-way ANOVA p,0.0001).
Discussion
Preservation from demyelination and enhancement of remye-
lination are important aims in multiple sclerosis research.
Recently, beneficial effects of FAE could be evaluated in
MOG-EAE studies in mice as well as in a phase II study in
MS patients [2,8]. Still the mode of action of FAE is not clear and
both immunomodulatory and neuroprotective factors have been
hypothesised. In this study, the potential of FAE to reduce
demyelination and/or to enhance remyelination was investigated
in the toxic cuprizone model. The cuprizone model is widely used
to study experimental de- and remyelination in mice [11,29].
Since no breakdown of the blood-brain-barrier (BBB) occurs
[30,31], the cuprizone model offers the opportunity to investigate
de- and remyelination without influence of the periphery.
Feeding mice 5 weeks with cuprizone induces nearly complete
demyelination in the white matter of the corpus callosum. After
withdrawal of the toxin spontaneous remyelination occurs [25].
In the current study, mice treated with MMF exhibited showed
no difference in myelin protein expression during demyelination
in the corpus callosum after 5 weeks of cuprizone treatment. At
the end of this period there was a slightly accelerated
remyelination in MMF treated animals when assessed by LFB
and MBP stainings. This was also evident one week after
cessation of cuprizone feeding with slightly higher expression of
MOG and PLP in MMF treated mice. Since cortical myelin loss
is also a prominent feature in this model [12], de- and
remyelination in the cerebral cortex were also investigated.
However, DMF and MMF treatment did not significantly change
cortical de- and remyelination.
Preceding demyelination, severe depletion of mature oligoden-
drocytes was observed in the corpus callosum after 4 weeks of
cuprizone feeding, while increasing again by weeks 5 and 6. This is
in accordance with findings on oligodendrocyte loss in cuprizone
induced demyelination [32,33]. However, no protective effect on
oligodendrocytes could be observed in animals treated with FAE.
Figure 4. Analysis of cytoprotetive properties of MMF and DMF
on the CG4 cell line in vitro. CG4 cells were incubated with various
concentrations (5, 10, 50mM/ml) of MMF and DMF (A). Cytotoxicity was
induced with 0.09mM H2O2 for 24h (B) and 1mM SNP as NO donor (C).
Cell toxicity was measured after 24h using AlamarBlueH. All data
represent relative cell numbers to the daily untreated control from
three independent experiments 6 SEM. CO: medium control.
doi:10.1371/journal.pone.0011769.g004
Figure 5. Influence of DMF and MMF on NO production of LPS
stimulated microglia. After stimulation for 24 h with 10 ng/ml LPS a
dose dependent decrease of NO production in cells incubated with
DMF (5, 10, 50mM/ml) could be observed. All data represent three
independent experiments compared to a daily standard curve using
known concentrations of sodium nitrite in culture medium. Results are
shown as means 6 SEM. Significant post hoc effects versus controls
(treated with LPS) are indicated by asterisks (*p,0.05, **p,0.01,
***p,0.001). CO: medium control without LPS.
doi:10.1371/journal.pone.0011769.g005
Fumatates in CNS Demyelination
PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11769Since cuprizone feeding decelerates the differentiation of oligo-
dendrocytes in vitro [34], the impact of FAE treatment on OPC
numbers during de- and remyelination was also investigated.
However, FAE had no effect on OPC numbers in our in vivo
model. Along with demyelination microgliosis and astrogliosis
occurred in the corpus callosum. Again, no significant differences
were observed in FAE treated animals.
Because in the cuprizone model no breakdown of the BBB
occurs, blood macrophages and T-cells do not enter the CNS. In
contrast to our in vivo results, in EAE experiments fumarates led
to a reduced Mac-3 positive microglia/macrophage inflammation
in the spinal cord as well as a significantly therapeutic effect on
the disease course [8]. The differences observed in the EAE
model and the cuprizone model may be due to the influence of
fumarates on peripheral immune cells. Since both T-cells and
peripheral macrophages infiltrate the lesions in EAE this is not
the case in the cuprizone model. This is supported by our in vitro
results where fumarates had no cytoprotective effect on
oligodendroglial cells but influenced apoptosis of PBMC.
Furthermore, DMF reduced the NO burst in microglia which
may indirectly reduce demyelination. These results suggest that
the beneficial effects of fumaric acids in inflammatory CNS
diseases is rather mediated by the modulation of peripheral
immune cells and has only little protective effects on myelin
integrity and oligodendrocytes. Since there is only little axonal
damage in cuprizone induced demyelination (as compared to the
EAE model) this model may not be optimal for the investigation
of a direct neuroprotective effect on axons and neurons. Finally,
the failure of fumarates to enhance remyelination may also be
due to the extremely strong and successful spontaneous
remyelination in the cuprizone model. Re-expression of myelin
proteins was nearly complete after already one week of
remyelination (see Fig. 1) and thus a small effect to accelerate
remyelination may not be evident.
In conclusion, we could demonstrate that FAE have no
influence on demyelination and only minor effects on remyelina-
tion in cuprizone induced myelin loss. The effect of FAE on
apoptosis of peripheral T-cells rather suggests that a major
contributor to the beneficial effects of FAE observed in EAE and
MS may be due to the modulation of peripheral immune cells that
cross the BBB.
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